A Phase 1 Dose Escalation Study of Cu(II)ATSM Administered Orally to Patients With Early Idiopathic Parkinson's Disease
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Jun 2019
Price : $35 *
At a glance
- Drugs Cu(II) ATSM (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Collaborative Medicinal Development
- 23 Jun 2019 Planned End Date changed from 1 Mar 2019 to 30 Nov 2019.
- 23 Jun 2019 Planned primary completion date changed from 1 Nov 2018 to 30 Nov 2019.
- 23 Jun 2019 Status changed from recruiting to active, no longer recruiting.